Neu ología
38
(2023)
326—333
NEUROLOGÍA
www.else ie .es/neu ologia
ORIGINAL
ARTICLE
Clinical
u ili y
o
a
pe sonalized
and
long- e m
moni o ing
de ice
o
Pa kinson’s
disease
in
a
eal
clinical
p ac ice
se ing:
An
expe
opinion
su ey
on
STAT-ONTM
D.
San os
Ga cíaa,∗,
N.
López
A iz eguib,
E.
Cuboc,
A.
Vinag e
A agónd,
R.
Ga cía-Ramose,
C.
Bo ué ,
G.
Fe nández-Paja íng,
N.
Caballolh,
I.
Caboi,
J.M.
Ba ios-Lópezj,
J.
He nández
Va a k,
M.A.
Á ila
Ri e al,
C.
Gasca-Salasm,
S.
Escalan en,
P.
Man ique
de
La ao,
R.
Pé ez
Nogue ap,
M.
Ál a ez
Saucoq,
M.
Sie a ,
M.H.G.
Monjem,
A.
Sánchez
Fe om,
S.
No o
Pon es,
F.
Alonso-F eche,
D.
Macías-Ga cía ,
I.
Lega dau,
A.
Rojo ,
I.
Ál a ez
Fe nándezw,
M.T.
Buongio now,
P.
Pas o w,
P.
Ga cía
Ruízx
aCHUAC,
Complejo
Hospi ala io
Uni e si a io
de
A
Co u˜
na,
Spain
bComplejo
Hospi ala io
de
Toledo,
Toledo,
Spain
cComplejo
Asis encial
Uni e si a io
de
Bu gos,
Bu gos,
Spain
dHospi al
Donos ia,
San
Sebas ián,
Spain
eHospi al
Clínico
San
Ca los,
Mad id,
Spain
Hospi al
In an a
So ía,
Mad id,
Spain
gComplejo
Hospi ala io
Uni e si a io
de
San iago
de
Compos ela
(CHUS),
Spain
hConso ci
Sani a i
In eg al,
Hospi al
Moisés
B oggi,
San
Joan
Despí,
Ba celona,
Spain
iComplejo
Hospi ala io
Uni e si a io
de
Pon e ed a
(CHOP),
Pon e ed a,
Spain
jHospi al
Uni e si a io
Vi gen
de
las
Nie es,
G anada,
Spain
kHospi al
Uni e si a io
Vall
d’Heb on,
Ba celona,
Spain
lConso ci
Sani a i
In eg al,
Hospi al
Gene al
de
L’Hospi ale ,
L’Hospi ale
de
Llob ega ,
Ba celona,
Spain
mCINAC,
Hospi al
Pue a
del
Su ,
Mad id,
Spain
nHospi al
de
To osa
Ve ge
de
la
Cin a
(HTVC),
To osa,
Ta agona,
Spain
oClínica
Uni e sidad
de
Na a a,
Pamplona,
Spain
pHospi al
Uni e si a io
Vi gen
Maca ena,
Se illa,
Spain
qHospi al
Uni e si a io
de
Elche,
Spain
Hospi al
Uni e si a io
Ma qués
de
Valdecilla,
San ande ,
Spain
sHospi al
Pue a
de
Hie o,
Mad id,
Spain
Hospi al
Uni e si a io
Vi gen
del
Rocío,
Se illa,
Spain
uHospi al
Uni e si a io
Son
Espases,
Palma
de
Mallo ca,
Spain
Hospi al
Uni e si a io
P íncipe
de
As u ias,
Alcalá
de
Hena es,
Mad id,
Spain
wHospi al
Uni e si a i
Mu ua
de
Te assa,
Te assa,
Ba celona,
Spain
xHospi al
Fundación
Jiménez
Díaz,
Mad id,
Spain
Recei ed
6
Augus
2020;
accep ed
5
Oc obe
2020
A ailable
online
25
Decembe
2020
∗Co esponding
au ho .
E-mail
add ess:
[email p o ec ed]
(D.
San os
Ga cía).
h ps://doi.o g/10.1016/j.n l.2020.10.013
0213-4853/©
2020
Sociedad
Espa˜
nola
de
Neu olog´
ıa.
Published
by
Else ie
Espa˜
na,
S.L.U.
This
is
an
open
access
a icle
unde
he
CC
BY-NC-ND
license
(h p://c ea i ecommons.o g/licenses/by-nc-nd/4.0/).
Neu ología
38
(2023)
326—333
KEYWORDS
De ice;
Fluc ua ions;
Hol e ;
Moni o ing;
Mo o
complica ions;
Pa kinson’s
disease
Abs ac
Backg ound:
STAT-ONTM is
an
objec i e
ool
ha
egis e s
ON-OFF
fluc ua ions
making
possible
o
know
he
s a e
o
he
pa ien
a
e e y
momen
o
he
day
in
no mal
li e.
Ou
aim
was
o
analyze
he
opinion
o
di e en
Pa kinson’s
disease
expe s
abou
he
STAT-ONTM ool
a e
using
he
de ice
in
a
eal
clinical
p ac ice
se ing
(RCPS).
Me hods:
STAT-ONTM was
p o ided
by
he
Company
Sense4Ca e
o
Spanish
neu ologis s
o
using
i
in
a
RCPS.
Each
neu ologis
had
he
de ice
o
a
leas
h ee
mon hs
and
could
use
i
in
PD
pa ien s
a
his/he
own
disc e ion.
In
Feb ua y
2020,
a
su ey
wi h
30
ques ions
was
sen
o
all
pa icipan s.
Resul s:
Two
hi ds
o
neu ologis s
(53.8%
emales;
mean
age
44.9
±
9
yea s
old)
wo ked
in
a
Mo emen
Diso de s
Uni ,
he
a e age
expe ience
in
PD
was
16
±
6.9
yea s,
and
40.7%
o
hem
had
p e iously
used
o he
de ices.
A
o al
o
119
e alua ions
we e
pe o med
in
114
pa ien s
( ange
2—9
by
neu ologis ;
mean
4.5
±
2.3).
STAT-ONTM was
conside ed
‘‘qui e’’
o
‘‘ e y
use ul’’
by
74%
o
he
neu ologis s
wi h
an
o e all
opinion
o
6.9
±
1.7
(0,
wo s ;
10,
bes ).
STAT-ONTM was
conside ed
be e
han
dia ies
by
70.3%
o
neu ologis s
and
a
use ul
ool
o
he
iden ifica ion
o
pa ien s
wi h
ad anced
PD
by
81.5%.
P ope
iden ifica ion
o
eezing
o
gai
episodes
and
alls
we e
equen
limi a ions
epo ed.
Conclusion:
STAT-ONTM could
be
a
use ul
de ice
o
using
in
PD
pa ien s
in
clinical
p ac ice.
©
2020
Sociedad
Espa˜
nola
de
Neu olog´
ıa.
Published
by
Else ie
Espa˜
na,
S.L.U.
This
is
an
open
access
a icle
unde
he
CC
BY-NC-ND
license
(h p://c ea i ecommons.o g/licenses/by-nc-nd/
4.0/).
PALABRAS
CLAVE
Disposi i o;
Fluc uaciones;
Hol e ;
Moni o eo;
Complicaciones
mo o as;
En e medad
de
Pa kinson
U ilidad
clínica
del
disposi i o
pa a
la
moni o ización
pe sonalizada
de
la
en e medad
de
Pa kinson,
STAT-ON,
en
condiciones
de
p ác ica
clínica
dia ia:
esul ados
de
una
encues a
de
opinión
de
neu ólogos
expe os
Resumen
In oducción:
STAT-ON
es
un
disposi i o
que
egis a
las
fluc uaciones
on-o
que
pe mi e
conoce
el
es ado
del
pacien e
con
en e medad
de
Pa kinson
(EP)
en
cada
momen o
del
día.
Nues o
obje i o
ue
analiza
la
opinión
de
di e en es
expe os
en
EP
sob e
STAT-ON,
después
de
usa
el
disposi i o
en
un
en o no
de
p ác ica
clínica
eal
(PCR).
Mé odos:
STAT-ON
ue
p opo cionado
po
la
compa˜
nía
Sense4Ca e
a
neu ólogos
espa˜
noles
pa a
usa lo
en
PCR.
Cada
neu ólogo
dispuso
del
disposi i o
du an e
al
menos
es
meses
y
podía
usa lo
en
pacien es
con
EP,
según
su
c i e io.
En
eb e o
de
2020,
se
en ió
una
encues a
con
30
p egun as
a
odos
los
pa icipan es.
Resul ados:
Dos
e cios
de
los
neu ólogos
(53,8%
muje es;
edad
p omedio
44,9
±
9
a˜
nos)
a-
bajaban
en
una
Unidad
de
T as o nos
del
Mo imien o,
con
una
expe iencia
en
EP
de
16
±
6,9
a˜
nos,
habiendo
el
40,7%
usado
o os
disposi i os
p e iamen e.
Se
ealiza on
un
o al
de
119
e aluaciones
en
114
pacien es
( ango
dos
a
nue e
po
neu ólogo;
media
4,5
±
2,3).
STAT-ON
ue
conside ado
«bas an e»
a
«muy
ú il»
po
el
74%
de
los
neu ólogos,
con
una
opinión
gene al
de
6,9
±
1,7
(0,
peo ;
10,
mejo ).
STAT-ON
ue
conside ado
mejo
que
los
dia ios
po
el
70,3%
de
los
neu ólogos
y
una
he amien a
ú il
pa a
la
iden ificación
de
pacien es
con
EP
a anzada
po
un
81,5%.
La
iden ificación
adecuada
de
los
episodios
de
congelación
de
la
ma cha
y
las
caídas
ue on
las
limi aciones
más
epo adas.
Conclusiones:
STAT-ON
pod ía
se
un
disposi i o
ú il
pa a
usa
en
la
PCR.
©
2020
Sociedad
Espa˜
nola
de
Neu olog´
ıa.
Publicado
po
Else ie
Espa˜
na,
S.L.U.
Es e
es
un
a ´
ıculo
Open
Access
bajo
la
licencia
CC
BY-NC-ND
(h p://c ea i ecommons.o g/licenses/by-
nc-nd/4.0/).
In oduc ion
The
symp oma ic
ea men
o
Pa kinson’s
disease
(PD)
wi h
cu en
he apies
is
e ec i e.
Howe e ,
o e
ime,
mo o
complica ions
appea ,
impac ing
on
he
pa ien ’s
quali y
o
li e
and
he
au onomy
o
pe o ming
daily-li ing
ac i i ies.
Al hough
p e ious
epo s
demons a ed
ha
app oxima ely
40%
o
PD
pa ien s
who
we e
ea ed
wi h
le odopa
o
4—6
yea s
expe ienced
mo o
complica ions,1s udies,
examin-
ing
mo e
specifically
wea ing-o ,
ha e
obse ed
ha
his
is
a
po en ially
ea ly
phenomenon.
As
an
example,
his
mani-
es a ion
a ec s
al eady
42%
o
he
PD
pa ien s
wi h
<2.5
yea s
disease
when
a
sc eening
ool
was
used
(WOQ-19)
and
21%
acco ding
o
a
neu ologis
assessmen .2Ga he -
ing
accu a e
in o ma ion
abou
he
clinical
s a us
o
he
pa ien
is
essen ial
o
planning
ea men
and
assessing
i s
e ec .
Daily
mo o
unc ion
assessmen
wi h
pape
dia ies
o
de ec ing
ime
pe iods
o
he
day
du ing
he
OFF
s a e,
ON
s a e
wi hou
dyskinesia
and
ON
s a e
wi h
disabling
o
non-disabling
dyskinesia,
esul
in
issues
o
compliance
and
327
D.
San os
Ga cía,
N.
López
A iz egui,
E.
Cubo
e
al.
eliabili y.3Elec onic
dia ies
ha e
he
ad an ages
o
acil-
i a ing
he
ansmission
o
he
in o ma ion
di ec ly
by
PD
pa ien s.
S ill
bo h
ype
o
dia ies,
pape
and
elec onic,
a e
limi ed
by
compliance
and
eliabili y
issues.
Impo an ly,
p e ious
s udies
ha e
shown
ha
dia ies
esul ed
in
a e age
esponse
compliance
o
app oxima ely
1
h.4The e o e,
mo e
objec i e
and
p ecise
sys ems
a e
necessa y
o
complemen
dia ies.
Wea able
ine ial
senso s
ha e
been
widely
used
o
moni o
he
mo o
s a us
and
analyze
symp oms
o
PD
such
as
emo ,
b adykinesia,
o
dyskinesia.5—12
The
REMPARK
sys em
(REMPARK
Pe sonal
heal h
de ice
o
he
emo e
and
au onomous
managemen
o
Pa kinson’s
disease,
FP7
p ojec
REMPARK
ICT-287677)
is
a
wea able
sys em,
de eloped
be ween
2011
and
2015,
o
moni o
mo o
s a es
h ough
a
sys em
equi ing
a
single
senso .13,14
Analogous
o
he
‘‘Hol e ’’
o
he
moni o ing
o
ca diac
pa ame e s,
he
REMPARK
sys em
has
been
designed
o
eco d
he
pa ien ’s
mo o
condi ion
du ing
dayligh
hou s
and
o
aid
in
managing
he
disease
ia
he
sma phone.
By
using
a
single
senso
(an
ine ial
measu emen
uni
called
9
×
3)
ad anced
algo i hms,
and
signal
p ocessing
me hods,
his
sys em
moni o s
and
eco ds
PD
mo o
mani es a ions.15
The
de ice
con ains
an
accele ome e ,
echa geable
ba -
e y
o
7
days,
da a
s o age
o
a
leas
1
yea .
I
is
able
o
acqui e
and
s o e
aw
ine ial
da a
o
a ificial
in elli-
gence
algo i hmic
aining
pu poses.
I
has
been
ma ke ed
as
STAT-ONTM by
he
Company
Sense4Ca e.
STAT-ONTM p o-
ides
in o ma ion
abou
b adykinesia
index
based
on
fluidi y
mo emen s,
dyskinesia,
eezing
o
gai
(FOG),
ON
and
OFF
s a es,
gai
pa ame e s
(speed
o
s ide,
cadence,
ime
walking,
s ep
leng h,
numbe
o
s eps),
numbe
o
alls
and
ene gy
expendi u e
and
pos u es.
STAT-ONTM demon-
s a ed
an
o e all
classifica ion
accu acy
o
92.2%
o
de ec
OFF
pe iods
unde
eal
condi ions
o
use
in
23
ad anced
PD
pa ien s
wea ing
he
kinema ic
senso
o
1—3
days
a
home.16 Mo e
ecen ly,
i
demons a ed
in
41
pa ien s
wi h
mode a e
o
se e e
idiopa hic
PD
using
he
sys em
in
he
sensi i i y
and
88%
specifici y
in
de ec ing
OFF
s a es.16,17 Al hough
he e
a e
no
cos /e ec i eness
s udies,
he
use
o
he
de ice
could,
hypo he ically,
help
o
iden i y
mo o
fluc ua ions
p ope ly,
which
could
imp o e
wi h
an
adequa e
ea men
op imiza ion.
This
could
help
educe
cos s
(e.g.,
eme gency
assis ance,
ins i u ionaliza ion,
e c.).
Despi e
he
mul iple
s udies
showing
he
accu acy
o
he
sys em
o
de ec
mo o
fluc ua ions,
he e
is
no
in o ma ion
abou
i s
possible
clinical
u ili y.
He e,
we
epo
he
opin-
ion
o
di e en
PD
expe
neu ologis s
abou
he
STAT-ONTM
u ili y
in
a
eal
clinical
p ac ice
se ing
(RCPS).
Me hods
CE
Ma k
Medical
De ice
STAT-ONTM was
p o ided
by
he
Com-
pany
Sense4Ca e
o
di e en
Spanish
neu ologis s
o
using
i
in
a
RCPS
be ween
Oc obe
and
Decembe
2019.
All
neu-
ologis s
we e
selec ed
because
hey
we e
PD
expe s.
Each
neu ologis
had
he
oppo uni y
o
use
he
de ice
in
PD
pa ien s
o
a
leas
3
mon hs
a
his/he
own
disc e ion.
In
Feb ua y
2020,
a
su ey
wi h
30
ques ions
on
STAT-ONTM
u ili y
was
sen
o
all
pa icipan s
(Supplemen a y
Ma e ial).
The
da a
was
anonymized
and
h ee
wa es
we e
made
o
ob ain
he
esponses.
The
pa icipa ion
was
olun a y.
S anda d
p o ocol
app o als,
egis a ions,
and
pa ien
consen s
Since
he
p esen
s udy
was
an
anonymized
opinion
su ey
abou
he
use ulness
o
a
CE
ma ke ed
de ice
o
clinical
p ac ice
use,
app o al
was
no
sough
om
any
e hics
com-
mi ee.
No
pa ien
da a
was
eco ded.
Da a
a ailabili y
The
p o ocol,
s a is ical
analysis
plan
and
uniden ifiable
da a
a e
a ailable
upon
eques .
Da a
analysis
Da a
we e
p ocessed
using
SPSS
20.0
o
Windows.
A
fi s
desc ip i e
analysis
was
ca ied
ou
in
which
he
esul s
we e
shown
in
coun s
(pe cen ages)
o
as
mean
±
de ia ion
acco ding
o
he
ype
o
a iable.
Depending
on
he
esul s
o
he
fi s
analysis,
co ela ion
be ween
specific
a ia-
bles
we e
analyzed.
The
S uden ’s
- es ,
Mann—Whi ney
U
es ,
Chi-squa e
es
o
Fishe
es
we e
used
as
app op i-
a e
(no mali y
assump ion
was
e ified
wi h
a
one-sample
Kolmogo o —Smi no
es ).
Spea man’s
o
Pea son’s
co ela-
ion
coe ficien
we e
also
used
o
analyzing
he
ela ionship
be ween
con inuous
a iables
depending
also
on
he
da a
dis ibu ion.
Co ela ions
we e
conside ed
weak
o
coe fi-
cien
alues
≤0.29,
mode a e
o
alues
be ween
0.30
and
0.59,
and
s ong
o
alues
≥0.60.
The
alue
o
p
was
con-
side ed
significan
when
i
was
<0.05.
Resul s
A
o al
o
37
neu ologis s
om
35
Spanish
cen e s
ecei ed
he
de ice
om
he
manu ac u e
o
using
i
in
PD
pa ien s
in
a
RCPS.
Twen y-se en
su eys
(73%)
we e
ecei ed
(53.8%
emales;
mean
age
44.9
±
9
yea s
old).
Two
hi ds
o
he
neu ologis s
wo ked
in
a
Mo emen
Dis-
o de s
Uni ,
he
mean
expe ience
on
PD
was
o
16
±
6.9
yea s,
and
40.7%
o
hem
had
used
p e iously
di e en
de ices
o
PD.
A
o al
o
119
e alua ions
in
114
pa ien s
( ange
om
2
o
9
pe
neu ologis ;
mean
4.5
±
2.3)
we e
pe -
o med.
Using
a
sco e
om
1
(unhelp ul)
o
7
( e y
help ul),
he
opinion
abou
di e en
usabili y
aspec s
was
eco ded
(Table
1).
ON-OFF
daily
dis ibu ion
was
he
bes
sco ed
(5.5
±
1.5)
whe eas
alls
de ec ion
he
wo s
(3.6
±
2).
The
subjec i e
gene al
opinion
abou
he
de ice
( om
0,
he
wo s ,
o
10,
he
bes )
was
6.9
±
1.7.
STAT-ONTM was
conside ed
be e
han
he
dia ies
by
70.3%
o
he
neu ologis s
(Fig.
1A)
and
a
use ul
de ice
o
iden i ying
ad anced
PD
pa ien s
by
81.5%.
A
high
pe cen -
age
o
PD
pa ien s
we e
conside ed
ha
could
benefi
om
using
STAT-ONTM (Fig.
1B).
STAT-ONTM was
conside ed
om
qui e
o
e y
use ul
by
74%
o
he
neu ologis s
(Fig.
1C).
A
significan
mode a e
posi i e
co ela ion
was
obse ed
be ween
he
numbe
o
assessmen s
pe o med
and
he
328
Neu ología
38
(2023)
326—333
Table
1
Sco e
om
1
(unhelp ul)
o
7
( e y
help ul)
o
he
opinion
abou
di e en
usabili y
aspec s
o
he
STAT-ON
de ice.
Pa ame e
Mean
±
SD
Range
n
ON—OFF
daily
dis ibu ion
5.5
±
1.5
2—7
27
Weekly
hou s
du ing
he
OFF
s a e
dis ibu ion
5.1
±
1.4
1—7
27
Dyskinesia
dis ibu ion
4.7
±
1.9
1—7
27
FOG
episodes
dis ibu ion
4.1
±
1.7
1—7
27
Numbe
o
FOG
episodes
and
du a ion
3.7
±
1.7
1—7
27
Falls
de ec ion 3.6
±
2.0
0—7
25
Da a
abou
gai 4.6
±
1.4 0—7 25
Amoun
o
mo emen 4.7
±
1.5 1—7 23
FOG,
eezing
o
gai ;
SD,
s anda d
de ia ion.
Figu e
1
A.
Opinion
abou
STAT-ONTM compa ed
o
OFF-ON
dia ies.
B.
Pe cen age
o
Pa kinson’s
disease
pa ien s
(1-25%
s
26-50%
s
51-75%
s76-100%
o
all
Pa kinson’s
disease
pa ien s
assessed
in
eal
clinical
p ac ice
se ing)
who,
e alua ed
in
daily
clinical
p ac ice,
a
he
disc e ion
o
he
e alua o ,
could
benefi
om
he
usage
o
STAT-ONTM.
C.
Use ulness
o
he
in o ma ion
collec ed
wi h
he
de ice.
gene al
opinion
abou
he
de ice
(
=
0.403;
p
=
0.046).
By
he
con a y,
no
di e ences
we e
obse ed
in
he
gene al
opinion
abou
he
de ice
( om
0
o
10)
wi h
espec
o
he
age
o
he
PD
expe
(
=
0.030;
p
=
0.830),
he
numbe
o
yea s
ea ing
PD
pa ien s
(
=
0.032;
p
=
0.881),
he
p e ious
use
o
de ices
o
PD
(7.2
±
2.1
s
6.9
±
1.5;
p
=
0.703),
and
he
p ac ice
se ing
(Mo emen
Diso de s
Uni
s.
s anda d
ou pa ien
clinic)
(7.2
±
2.3
s
6.9
±
1.5;
p
=
0.784).
STAT-ONTM was
specifically
used
by
13
o
he
27
neu olo-
gis s
(48.1%)
in
21
ad anced
PD
pa ien s
who
we e
ea ed
wi h
an
ad anced
he apy:
10
deep
b ain
s imula ion
(DBS);
6
subcu aneous
apomo phine
in usion;
3
in aduodenal
le -
odopa
in usion
(2
wi hou
in o ma ion).
Only
one
neu ologis
conside ed
STAT-ONTM as
no
use ul
in
hese
pa ien s.
Six y
h ee
pe cen
conside ed
i
om
qui e
o
e y
use ul
(N
=
11;
2
wi hou
answe )
o
using
in
his
popula ion
and
wi h
a
pe iodici y
ha
should
be
indi idualized
(67%).
Wi h
ega ds
o
he
limi a ions
o
he
in o ma ion
p o-
ided
by
he
de ice
o
o he
ela ed
usabili y
p oblems,
17
neu ologis s
(63%)
demanded
o he
ele an
in o ma ion
o
ound
p oblems
(Table
2).
The
mos
equen
we e
p ob-
lems
wi h
he
in e p e a ion
o
ime
in
g ay
colo
and
p ope
iden ifica ion
o
eezing
o
gai
(FOG)
episodes
and/o
alls.
Almos
89%
o
he
neu ologis s
conside ed
ha
he
sen-
so
had
a
pleasan
appea ance
o
he
pa ien
and
ha
he
wais
was
a
p ope
place
o
wea ing
i .
Mo eo e ,
85%
o
he
neu ologis s
conside ed,
based
on
hei
expe ience
using
he
sys em,
ha
he
pa ien ’s
opinion
abou
he
de ice
was
good.
Howe e ,
he
ime
in es ed
in
explaining
he
pa ien
Table
2
Limi a ions
o
he
in o ma ion
p o ided
by
he
de ice
eco ded
by
he
neu ologis s.
Limi a ion
epo ed
n
P oblems
wi h
he
in e p e a ion
o
ime
inac i e
6
P ope
iden ifica ion
o
FOG
episodes
and/o
alls
5
No
di e en ia ion
be ween
disabling
and
non-disabling
dyskinesia
3
No
in o ma ion
abou
he
ela ion
be ween
s a es
and
he
ime
o
aking
he
medica ion
2
No
iden ifica ion
o
emo
1
No
iden ifica ion
o
non-mo o
symp oms
1
No
iden ifica ion
o
unk
la e aliza ion
1
No
iden ifica ion
o
mo o
s a us
du ing
sleep
1
P oblems
wi h
he
bel
whe e
he
de ice
is
placed
1
T aining
is
necessa y
o
he
pa ien
and
doc o
1
FOG,
eezing
o
gai .
he
de ice
and
he
analysis
o
he
esul s
was
conside ed
a
limi a ion
by
he
40.7%
o
he
neu ologis s.
Impo an ly,
89%
would
use
he
de ice
in
hei
daily
clinical
p ac ice.
In
Supplemen a y
Ma e ial
all
he
in o ma ion
abou
he
answe s
o
he
30
ques ions
o
he
su ey
is
shown.
329
D.
San os
Ga cía,
N.
López
A iz egui,
E.
Cubo
e
al.
Discussion
This
is
he
fi s
publica ion
abou
he
opinion
o
a
g oup
o
PD
expe s
on
he
STAT-ONTM sys em
a e
using
i
in
a
RCPS.
In
gene al,
he
opinion
was
a o able
al hough
he e
a e
aspec s
ha
could
be
imp o ed.
Despi e
he
analysis
being
based
on
su ey
da a,
i
is
aluable
as
i
has
been
ca ied
ou
by
an
independen
la ge
g oup
o
expe s
in
PD,
wi h
p e ious
expe ience
wi h
o he
de ices
o
moni o
he
disease,
and
a e
ha ing
join ly
e alua ed
mo e
han
100
pa ien s
wi h
his
no el
sys em.
STAT-ONTM is
a
non-in asi e
Class
II
A
medical
de ice
acco ding
o
Di ec i e
93/42/EEC
ha
has
been
de eloped
a e
di e en
R&D
Eu opean
p ojec s
since
2009
and
being
alida ed
in
di e en
clinical
s udies.13—23 Howe e ,
un il
now,
no
in o ma ion
abou
he
opinion
o
he
neu ologis s
on
STAT-ONTM a e
using
i
in
a
RCPS
had
been
epo ed.
In
ou
s udy,
he
su ey
esponse
a e
was
accep able
(73%).24 Addi ional
s eng hs
o
he
s udy
we e
he
e e ed
expe ience
on
PD
o
he
neu ologis s,
he
numbe
o
neu ol-
ogis s
who
pa icipa ed
and
he
ac
ha
he
ques ionnai e
was
anonymous
and
he
esponses
we e
independen .
The
bes
sco ed
pa ame e s
abou
he
usabili y
o
STAT-ONTM
we e
‘‘ON-OFF
daily
dis ibu ion’’
and
‘‘Weekly
hou s
du ing
he
OFF
s a e
dis ibu ion’’,
ag eeing
wi h
he
p io
e i-
dence
on
he
abili y
o
he
sys em
o
de ec
ON-OFF
s a es
in
PD
pa ien s
in
eal
condi ions.16,17 One
o
he
main
ad an-
ages
o
he
sys em
is
ha
pa ien s
need
o
wea
only
a
single
senso ,
making
i
compa ible
wi h
an
ac i e
li e.
Pa icipan s
in
p e ious
s udies
conside ed
STAT-ONTM o
be
use - iendly
and
we e
sa isfied
wi h
he
sys em,16,25 being
hese
findings
in
acco dance
wi h
he
opinion
exp essed
by
he
neu ologis s
in
he
su ey.
One
o
he
impo an
findings
is
ha
a
la ge
majo -
i y
o
he
neu ologis s
conside ed
STAT-ONTM o
be
a
be e
me hod
o
moni o ing
PD
pa ien s
han
dia ies.
Al hough
dia ies
ha e
been
used
in
ials
as
he
gold
s an-
da d,
wha
me hod
is
be e
has
no
been
epo ed
and
a
ial
o
compa ing
PD
hol e
s
PD
dia y
is
on-going
(h ps://clinical ials.go /c 2/show/NCT04176302).
A
sec-
ond
impo an
aspec
is,
as
he
esul
o
he
su ey
sugges ,
he
possibili y
o
using
STAT-ONTM in
a
high
pe cen age
o
PD
pa ien s
due
o
he
ac
ha
mo o
fluc ua ions
a e
e-
quen
and
disabling
e en
in
ea ly
PD
pa ien s.26 Finally,
a
e y
impo an
finding
is
ha
STAT-ONTM could
be
a
use ul
me hod
o
moni o ing
PD
pa ien s
unde
DBS
o
an
in u-
sion
he apy.27 Al hough
he
expe ience
was
limi ed
o
21
pa ien s
ea ed
by
13
neu ologis s,
10
ou
o
11
ha
eplied
o
he
su ey
s a ed
ha
STAT-ONTM could
be
use ul,
being
his
obse a ion
in e es ing
because
i
would
allow
o
mon-
i o
he
esponse
be o e
and
a e
he
he apy.
Since
hese
a e
expensi e
ea men s
and
no
ee
o
complica ions,
his
is
a
g ea
a ea
o
in e es
o
using
hese
new
sys ems.
STAT-ONTM is
an
objec i e
me hod
o
moni o ing
OFF-
ON
fluc ua ions.
Howe e ,
he
subjec i e
componen
o
he
pa ien ’s
opinion
is
necessa y
o
know
wha
happens
when
he
pa ien
is
no
mo ing
as
he
senso
does
no
collec
da a
in
inac i i y
pe iods.
This
limi a ion
was
he
mos
e-
quen ly
epo ed
and
should
be
aken
in o
accoun
when
using
STAT-ONTM in
pa ien s
who
spend
a
lo
o
ime
si -
ing
o
inac i e.
Al hough
p e ious
ials
demons a ed
a
high
sensi i i y
and
specifici y
o
de ec ing
dyskinesia
and
FOG,18,20—22 a
limi a ion
epo ed
by
he
neu ologis s
was
ha
he
de ice
was
no
capable
o
dis inguishing
disabling
and
non-disabling
dyskinesias.
Mo eo e ,
he
p ope
iden i-
fica ion
o
FOG
episodes
and/o
alls
was
he
second
mos
equen
limi a ion
epo ed.
Some
expe s
conside ed
ha
he
sys em
o e es ima ed
alls
in
some
ins ances.
In eg a ed
in o ma ion
on
medica ion
in ake
hou s
was
also
demanded
by
he
expe s.
Finally,
al hough
only
one
neu ologis
com-
men ed
he
ac
o
no
in o ming
abou
non-mo o
symp oms
as
a
limi a ion
o
he
sys em,
his
is
an
essen ial
poin
because
non-mo o
symp oms
a e
equen
and
ela ed
o
mo o
fluc ua ions.26,28 Al e na i ely,
he
pa ien
could
be
ained
o
p ess
he
ala m
bu on
when
a
specific
non-mo o
symp oms,
such
as
pain
o
anxie y,
appea
and
analyze
hei
appea ance
in
ela ion
o
he
mo o
s a e
a
ha
momen .29
The
de ice
was
used
a
o al
o
119
imes
in
114
pa ien s.
Howe e ,
he
a e age
use
by
neu ologis
was
less
han
fi e
wi h
a
ange
om
2
o
9
imes,
he
de ice
was
used
o
a
b ie
ime,
and
o
he
as
majo i y
i
was
hei
fi s
expe-
ience
wi h
he
sys em
(da a
no
collec ed)
being
necessa y
o
lea n
abou
he
usage
o
he
de ice,
so
ou
findings
on
he
possible
use ulness
o
STAT-ONTM o
moni o
PD
pa ien s
in
a
RCPS
should
be
conside ed
wi h
cau ion.
Al hough
81.5%
o
he
e alua o s
conside ed
ha
he
de ice
could
be
use-
ul
o
de ec ing
pa ien s
wi h
ad anced
PD,
ob iously,
i
is
an
opinion
su ey
and
no
a
s udy
designed
o
de e mine
he
sensi i i y
and
specifici y
o
he
de ice
o
de ec ing
ad anced
PD
based
on
defined
c i e ia
(e.g.,
CDEPA30).
The
ac
ha
he e
was
a
be e
opinion
on
he
de ice
in
mo e
equen
use s
should
be
confi med
in
u u e
s udies
o
ule
ou
di e en
pe cep ion
acco ding
o
echnology
adop ion
and
exposu e.
Finally,
o he
biases
ela ed
o
he
me hodol-
ogy
o
he
p esen
s udy
canno
be
excluded
(e.g.,
ques ion
ypes).
In
summa y,
his
is
he
fi s
opinion
su ey
o
a
g oup
o
PD
expe s
who
e alua ed
he
u ili y
o
STAT-ONTM in
a
RCPS.
STAT-ONTM could
be
a
use ul
de ice
o
moni o ing
PD
pa ien s
in
clinical
p ac ice.
Mo e
expe ience
is
needed
o
ha ing
a
con as ed
and
confiden
opinion.
Decla a ions
E hics
app o al
and
consen
o
pa icipa e
The
p esen
s udy
consis s
o
an
opinion
poll
and
he e
a e
no
iden ifiable
da a
collec ed
om
pa ien s
and/o
pa i-
cipan s.
The e o e,
i
does
no
equi e
he
app o al
o
an
e hical
commi ee.
The
fi s
au ho ,
Diego
San os
Ga cía,
is
a
membe
o
an
au onomous
e hics
commi ee,
he
‘‘Comi é
Au onómico
de
É ica
de
In es igación
de
Galicia’’,
and
is
ully
amilia
wi h
he
egula ions
as
hey
apply.
Consen
o
publica ion
No
applicable.
A ailabili y
o
da a
and
ma e ial
The
da ase s
used
and/o
analyzed
du ing
he
cu en
s udy
a e
a ailable
om
he
co esponding
au ho
on
easonable
eques .
330

Neu ología
38
(2023)
326—333
Au ho s’
con ibu ions
San os
Ga cía
D.:
concep ion,
o ganiza ion,
and
execu-
ion
o
he
p ojec ;
s a is ical
analysis;
w i ing
o
he
fi s
d a
o
he
manusc ip ;
e alua ion
o
pa icipan s;
su ey
esponse.
López
A iz egui
N.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Cubo
E.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Vinag e
A agón
A.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Ga cía-Ramos
R.:
e iew
and
c i ique;
e alua ion
o
pa -
icipan s;
su ey
esponse.
Bo ué
C.:
e iew
and
c i ique;
e alua ion
o
pa ici-
pan s;
su ey
esponse.
Fe nández-Paja ín
G.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Caballol
N.:
e iew
and
c i ique;
e alua ion
o
pa ici-
pan s;
su ey
esponse.
Cabo
I.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Ba ios
López
J
M.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
He nández
Va a
J.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Á ila
Ri e a
M.
A.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Gasca-Salas
C.:
e iew
and
c i ique;
e alua ion
o
pa i-
cipan s;
su ey
esponse.
Escalan e
S.:
e iew
and
c i ique;
e alua ion
o
pa ici-
pan s;
su ey
esponse.
Man ique
de
La a
P. :
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Pé ez
Nogue a
R.:
e iew
and
c i ique;
e alua ion
o
pa -
icipan s;
su ey
esponse.
Ál a ez
Sauco
M.:
e iew
and
c i ique;
e alua ion
o
pa -
icipan s;
su ey
esponse.
Sie a
M.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Monje
M.
H.
G.:
e iew
and
c i ique;
e alua ion
o
pa i-
cipan s;
su ey
esponse.
Sánchez
Fe o
A.:
e iew
and
c i ique;
e alua ion
o
pa -
icipan s.
No o
Pon e
S.:
e iew
and
c i ique;
e alua ion
o
pa i-
cipan s;
su ey
esponse.
Alonso-F ech
F. :
e iew
and
c i ique;
e alua ion
o
pa i-
cipan s;
su ey
esponse.
Macías-Ga cía
D.:
e iew
and
c i ique;
e alua ion
o
pa -
icipan s;
su ey
esponse.
Lega da
I.:
e iew
and
c i ique;
e alua ion
o
pa ici-
pan s;
su ey
esponse.
Rojo
A.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Ál a ez
Fe nández
I.:
e iew
and
c i ique;
e alua ion
o
pa icipan s;
su ey
esponse.
Buongio no
M.
T.:
e iew
and
c i ique;
e alua ion
o
pa -
icipan s;
su ey
esponse.
Pas o
P. :
e iew
and
c i ique;
e alua ion
o
pa icipan s.
Ga cía
Ruíz
P. :
e iew
and
c i ique;
e alua ion
o
pa i-
cipan s;
su ey
esponse.
Financial
disclosu es
San os
Ga cía
D.
has
ecei ed
hono a ia
o
educa ional
p esen a ions
and
ad ice
se ice
by
Abb ie,
UCB
Pha ma,
Lundbeck,
KRKA,
Zambon,
Bial
and
Te a.
López
A iz egui
N.
has
ecei ed
hono a ia
o
educa ional
p esen a ions
and
ad ice
se ice
by
Abb ie,
I al a maco,
Zambon,
and
Bial.
Cubo
E:
T a el
g an s:
Abb ie,
Alle gan,
Bos on;
Lec-
u ing
hono a ia:
Abb ie,
In e na ional
Pa kinson’s
disease
Mo emen
Diso de
Socie y.
Vinag e
A agón
A.
has
ecei ed
hono a ia
o
educa ional
p esen a ions
by
UCB
Pha ma.
Ga cía-Ramos
R.
has
ecei ed
hono a ia
o
educa ional
p esen a ions
and
ad ice
se ice
by
Abb ie,
Zambon,
Me z,
Alle gan,
Bial,
K ka,
Te a
and
I al a maco.
Bo ué
C.:
None.
Fe nández-Paja ín
G.
has
ecei ed
hono a ia
om
I al a -
maco,
Zambon
and
Bial
and
sponso ship
om
I al a maco,
Bos on
Scien ific
and
Zambon
o
a ending
con e ences.
Caballol
N.
has
ecei ed
hono a ia
om
Bial,
I al á maco,
Qualigen,
Zambon,
UCB,
Te a
and
KRKA
and
sponso ship
om
Zambon,
TEVA
and
Abb ie
o
a ending
medical
con-
e ences.
Cabo
I.
has
ecei ed
hono a ia
o
educa ional
p esen a-
ions
and
ad ice
se ice
by
Abb ie,
Zambon
and
Bial.
Ba ios
López
J.M.:
None.
He nández
Va a
J.
has
ecei ed
a el
bu sa ies
and
edu-
ca ional
g an s
om
Abb ie
and
has
ecei ed
hono a ia
o
educa ional
p esen a ions
om
Abb ie,
Te a,
Bial,
Zambon,
I al a maco
and
Sanofi-Genzyme.
Á ila
Ri e a
M.
A.
has
ecei ed
hono a ia
om
Zambon,
UCB
Pha ma,
Qualigen,
Bial,
and
Te a,
and
sponso ship
om
Zambon
and
Te a
o
a ending
con e ences.
Gasca-Salas
C.:
None.
Escalan e
S.
has
ecei ed
hono a ia
o
educa ional
p e-
sen a ions
and
ad ice
se ice
by
Abb ie,
Zambon,
and
Bial.
Man ique
de
La a
P. :
None.
Pé ez
Nogue a
R.:
Ál a ez
Sauco
M.
has
ecei ed
hono a ia
o
educa ional
p esen a ions
and
ad ice
se ice
by
Abb ie,
UCB
Pha ma,
Zambon,
Bial
and
Te a.
Sie a
M.
Monje
M.H.G.
has
ecei ed
speake
and
a el
hono a ia
om
No a is
Pha maceu ical.
She
is
employed
by
Fundación
HM
Hospi ales.
She
is
membe
o
he
Elec onic
De elop-
men
o
Ra ing
Scales
Commi ee
o
he
Mo emen
Diso de s
Socie y.
Sánchez
Fe o
A.
has
ecei ed
unding
om
he
Join
P og am
o
Neu odegene a i e
Diseases
(p ojec
Re e ence
Numbe :
HESOCARE-329-073)
and
has
also
ecei ed
speake
and
a el
hono a ia
om
Te a,
Zambon,
Abb ie,
and
No a is
Pha maceu ical.
He
is
employed
by
Leuko
Imag-
ing
Sys ems
S.L.
and
Fundación
HM
Hospi ales.
He
owns
common
s ock
in
Leuko
Labs,
Inc
a
company
wi h
comme -
cial
in e es s
in
a
Medical
De ice
de eloped
o
neu openia
de ec ion.
He
is
also
an
in en o
o
a
Me hod
and
Appa a us
o
Mo o
Func ion
cha ac e iza ion
(US
2020/0060622
Al)
ha
has
been
licensed
o
an
independen
comme cial
en i y
(nQ-Medical)
by
he
Massachuse s
o
Technology.
He
se es
as
Chai
o
he
Ad
Hoc
Commi ee
on
Technology
o
he
331
D.
San os
Ga cía,
N.
López
A iz egui,
E.
Cubo
e
al.
Spanish
Neu ological
Socie y,
Chai
o
Commi ee
on
Elec-
onic
De elopmen
o
Ra ing
Scales
o
he
Mo emen
Diso de s
Socie y
and
is
a
membe
o
he
Mo emen
Dis-
o de s
Socie y
Technology
Task o ce
and
Scien ific
and
Educa ion
(Eu opean
Sec ion)
Commi ee.
No o
Pon e
S.
has
ecei ed
un es ic ed
educa ional
sup-
po
om
Abb ie
and
Zambon
and
hono a ia
o
educa ional
p esen a ions
om
Abb ie
and
I al a maco.
Alonso-F ech
F. :
None.
Macías-Ga cía
D.
has
ecei ed
hono a ia
o
educa ional
p esen a ions
by
Abb ie,
Te a
and
Zambom.
Lega da
I.
has
ecei ed
hono a ia
o
educa ional
p esen-
a ions
and
ad ice
se ice
by
Abb ie,
UCB
Pha ma,
Zambon,
Bial
and
Te a.
Rojo
A.
has
ecei ed
a el
bu sa ies
om
Abb ie
and
Zambon
and
hono a ia
o
educa ional
p esen a ions
om
Te a,
Bial,
UCB
and
Zambon.
Ál a ez
Fe nández
I.:
None.
Buongio no
M.
T.:
None.
Pas o
P:
None.
Ga cía
Ruíz
P.
Conflic
o
in e es s
None.
This
wo k
has
been
ca ied
ou
absolu ely
indepen-
den ly
om
he
company
sense4ca e,
who
has
only
p o ided
he
de ices
and
has
no
pa icipa ed
in
i .
Appendix
A.
Supplemen a y
da a
Supplemen a y
da a
associa ed
wi h
his
a i-
cle
can
be
ound,
in
he
online
e sion,
a
doi:10.1016/j.n l.2020.10.013.
Re e ences
1.
Ahlskog
JE,
Muen e
MD.
F equency
o
le odopa- ela ed
dyski-
nesias
and
mo o
fluc ua ions
as
es ima ed
om
he
cumula i e
li e a u e.
Mo
Diso d.
2001;16:448—58.
2.
S occhi
F,
An onini
A,
Ba one
P,
Tinazzi
M,
Zappia
M,
Ono j
M,
e
al.
DEEP
s udy
g oup.
2014;20:204—11.
3.
Hause
RA,
Decke s
F,
Lehe
P.
A
home
dia y
o
assess
unc-
ional
s a us
in
pa ien s
wi h
Pa kinson’s
disease
wi h
mo o
fluc ua ions
and
dyskinesia.
Mo
Diso d.
2004;19:1409—13.
4.
Lyons
KE,
Pahwa
R.
Elec onic
mo o
unc ion
dia y
o
pa ien s
wi h
Pa kinson’s
disease:
a
easibili y
s udy.
Pa kinsonism
Rela
Diso d.
2007;13:304—7.
5.
Fishe
JM,
Hamme la
NY,
Ploe z
T,
And as
P,
Roches e
L,
Walke
RW.
Unsupe ised
home
moni o ing
o
Pa kinson’s
disease
mo o
symp oms
using
body-wo n
accele ome e s.
Pa kinsonism
Rela
Diso d.
2016;33:44—50.
6.
Me a
TO,
Filipkowski
DE,
Riley
DE,
Whi ney
CM,
Wal e
BL,
Gun-
zle
SA,
e
al.
Quan i a i e
analysis
o
gai
and
balance
esponse
o
deep
b ain
s imula ion
in
Pa kinson’s
disease.
Gai
Pos u e.
2013;38:109—14.
7.
Cancela
J,
Pas o ino
M,
A edondo
MT,
Niki a
KS,
Villag a
F,
Pas o
MA.
Feasibili y
s udy
o
a
wea able
sys em
based
on
a
wi eless
body
a ea
ne wo k
o
gai
assessmen
in
Pa kinson’s
disease
pa ien s.
Senso s
(Basel).
2014;14:4618—33.
8.
Tzallas
AT,
Tsipou as
MG,
Rigas
G,
Tsalikakis
DG,
Ka ounis
EC,
Chond ogio gi
M,
e
al.
PERFORM:
a
sys em
o
moni o -
ing
assessmen
and
managemen
o
pa ien s
wi h
Pa kinson’s
disease.
Senso s
(Basel).
2014;14:21329—57.
9.
Ho ne
MK,
McG ego
S,
Be gquis
F.
An
objec i e
fluc ua ion
sco e
o
Pa kinson’s
disease.
PLOS
ONE.
2015;10:e0124522.
10.
Godinho
C,
Domingos
J,
Cunha
G,
San os
AT,
Fe nandes
RM,
Ab eu
D,
e
al.
A
sys ema ic
e iew
o
he
cha ac e is ics
and
alidi y
o
moni o ing
echnologies
o
assess
Pa kinson’s
dis-
ease.
J
Neu oeng
Rehabil.
2016;13:24.
11.
Sánchez-Fe o
Á,
Elshehabi
M,
Godinho
C,
Salko ic
D,
Hobe
MA,
Domingos
J,
e
al.
New
me hods
o
he
assessmen
o
Pa kinson’s
disease
(2005
o
2015):
a
sys ema ic
e iew.
Mo
Diso d.
2016;31:1283—92.
12.
Espay
AJ,
Bona o
P,
Nahab
FB,
Mae zle
W,
Dean
JM,
Klucken
J,
e
al.,
Mo emen
Diso de s
Socie y
Task
Fo ce
on
Technology.
Technology
in
Pa kinson’s
disease:
challenges
and
oppo uni ies.
Mo
Diso d.
2016;31:1272—82.
13.
Samà
A,
Pé ez-López
C,
Rod íguez-Ma ín
D,
Mo eno-A ós egui
JM,
Ro i a
J,
Ahl ichs
C,
e
al.
A
double
closed
loop
o
enhance
he
quali y
o
li e
o
Pa kinson’s
Disease
pa ien s:
REMPARK
sys em.
S ud
Heal h
Technol
In o m.
2014;207:
115—24.
14.
Pé ez-López
C,
Samà
A,
Rod íguez-Ma ín
D,
Ca alà
A,
Cabes any
J,
Mo eno-A os egui
JM,
e
al.
Assessing
mo o
fluc-
ua ions
in
Pa kinson’s
disease
pa ien s
based
on
a
single
ine ial
senso .
Senso s
(Basel).
2016;16:2132.
15.
Rod íguez-Ma ín
D,
Pé ez-López
C,
Samà
A,
Ca alà
A,
Mo eno
A os egui
JM,
Cabes any
J,
e
al.
A
wais -wo n
ine ial
mea-
su emen
uni
o
long- e m
moni o ing
o
Pa kinson’s
disease
pa ien s.
Senso s
(Basel).
2017;17:827.
16.
Bayés
À,
Samá
A,
P a s
A,
Pé ez-López
C,
C espo-Ma a e
M,
Mo eno
JM,
e
al.
A
‘‘HOLTER’’
o
Pa kinson’s
disease:
alida-
ion
o
he
abili y
o
de ec
on-o
s a es
using
he
REMPARK
sys em.
Gai
Pos u e.
2018;59:1—6.
17.
Rod íguez-Moline o
A,
Pé ez-López
C,
Samà
A,
de
Mingo
E,
Rod íguez-Ma ín
D,
He nández-Va a
J,
e
al.
A
kinema ic
senso
and
algo i hm
o
de ec
mo o
fluc ua ions
in
Pa kinson
disease:
alida ion
s udy
unde
eal
condi ions
o
use.
JMIR
Rehabil
Assis
Technol.
2018;25:5,
e8.
18.
Samà
A,
Pé ez-Lopez
C,
Romagosa
J,
Rod íguez-Ma ín
D,
Ca alà
A,
Cabes any
J,
e
al.
Dyskinesia
and
mo o
s a e
de ec ion
in
Pa kinson’s
disease
pa ien s
wi h
a
single
mo emen
senso .
Con
P oc
IEEE
Eng
Med
Biol
Soc.
2012;2012:1194—7.
19.
Rod íguez-Moline o
A,
Samà
A,
Pé ez-Ma ínez
DA,
Pé ez
López
C,
Romagosa
J,
Bayés
À,
e
al.
Valida ion
o
a
po able
de ice
o
mapping
mo o
and
gai
dis u bances
in
Pa kinson’s
disease.
JMIR
Mheal h
Uheal h.
2015;3:e9.
20.
Pé ez-López
C,
Samà
A,
Rod íguez-Ma ín
D,
Mo eno-A ós egui
JM,
Cabes any
J,
Bayes
A,
e
al.
Dopamine gic-induced
dyskine-
sia
assessmen
based
on
a
single
bel -wo n
accele ome e .
A i
In ell
Med.
2016;67:47—56.
21.
Rod íguez-Moline o
A,
Samà
A,
Pé ez-López
C,
Rod íguez-
Ma ín
D,
Quinlan
LR,
Alcaine
S,
e
al.
Analysis
o
co ela ion
be ween
an
accele ome e -based
algo i hm
o
de ec ing
Pa kinsonian
gai
and
UPDRS
subscales.
F on
Neu ol.
2017;8:
431.
22.
Rod íguez-Ma ín
D,
Samà
A,
Pé ez-López
C,
Ca alà
A,
Mo eno
A os egui
JM,
Cabes any
J,
e
al.
Home
de ec ion
o
eezing
o
gai
using
suppo
ec o
machines
h ough
a
single
wais -wo n
iaxial
accele ome e .
PLOS
ONE.
2017;12:
e0171764.
23.
Samà
A,
Pé ez-López
C,
Rod íguez-Ma ín
D,
Ca alà
A,
Mo eno-
A ós egui
JM,
Cabes any
J,
e
al.
Es ima ing
b adykinesia
se e i y
in
Pa kinson’s
disease
by
analysing
gai
h ough
a
wais -
wo n
senso .
Compu
Biol
Med.
2017;84:114—23.
24.
B ick
JM,
Kal on
G.
Handling
missing
da a
in
su ey
esea ch.
S a
Me hods
Med
Res.
1996;5:215—38.
332
Neu ología
38
(2023)
326—333
25.
Fishe
JM,
Hamme la
NY,
Roches e
L,
And as
P,
Walke
RW.
Body-wo n
senso s
in
Pa kinson’s
disease:
e alua ing
hei
accep abili y
o
pa ien s.
Telemed
J
E
Heal h.
2016;22:63—9.
26.
San os-Ga cía
D,
de
Deus
Fon icoba
T,
Suá ez
Cas o
E,
Anei os
Díaz
A,
McA ee
D,
Ca alán
MJ,
e
al.,
COPPADIS
S udy
G oup.
Non-mo o
symp om
bu den
is
s ongly
co ela ed
o
mo o
complica ions
in
pa ien s
wi h
Pa kinson’s
disease.
Eu
J
Neu ol.
2020;27:1210—23.
27.
Mae zle
W,
Klucken
J,
Ho ne
M.
A
clinical
iew
on
he
de el-
opmen
o
echnology-based
ools
in
managing
Pa kinson’s
disease.
Mo
Diso d.
2016;31:1263—71.
28.
Ma inez-Fe nandez
R,
Schmi
E,
Ma inez-Ma in
P,
K ack
P.
The
hidden
sis e
o
mo o
fluc ua ions
in
Pa kinson’s
disease:
a
e iew
on
nonmo o
fluc ua ions.
Mo
Diso d.
2016;31:1080—94.
29.
Ma inez-Ma in
P,
Kulise sky
J,
Mi
P,
Tolosa
E,
Ga cía-Delgado
P,
Luquin
MR.
Valida ion
o
a
simple
sc eening
ool
o
ea ly
diagnosis
o
ad anced
Pa kinson’s
disease
in
daily
p ac ice:
he
CDEPA
ques ionnai e.
NPJ
Pa kinsons
Dis.
2018;4:20.
30.
Wi jas
T,
Kaphan
E,
Azulay
JP,
Blin
O,
Ceccaldi
M,
Pouge
J,
e
al.
Nonmo o
fluc ua ions
in
Pa kinson’s
disease:
equen
and
disabling.
Neu ology.
2002;59:408—13.
333